244 related articles for article (PubMed ID: 2060086)
1. Assessment of chemotherapy-associated nephrotoxicity in children with cancer.
Skinner R; Pearson AD; Coulthard MG; Skillen AW; Hodson AW; Goldfinch ME; Gibb I; Craft AW
Cancer Chemother Pharmacol; 1991; 28(2):81-92. PubMed ID: 2060086
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity after ifosfamide.
Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
Arch Dis Child; 1990 Jul; 65(7):732-8. PubMed ID: 2386379
[TBL] [Abstract][Full Text] [Related]
3. The influence of age on nephrotoxicity following chemotherapy in children.
Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
Br J Cancer Suppl; 1992 Aug; 18():S30-5. PubMed ID: 1503924
[TBL] [Abstract][Full Text] [Related]
4. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
[TBL] [Abstract][Full Text] [Related]
5. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
Ho PT; Zimmerman K; Wexler LH; Blaney S; Jarosinski P; Weaver-McClure L; Izraeli S; Balis FM
Cancer; 1995 Dec; 76(12):2557-64. PubMed ID: 8625085
[TBL] [Abstract][Full Text] [Related]
6. Nephrotoxicity in survivors of Wilms' tumours in the North of England.
Bailey S; Roberts A; Brock C; Price L; Craft AW; Kilkarni R; Lee RE; Skillen AW; Skinner R
Br J Cancer; 2002 Nov; 87(10):1092-8. PubMed ID: 12402147
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin dose rate as a risk factor for nephrotoxicity in children.
Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
Br J Cancer; 1998 May; 77(10):1677-82. PubMed ID: 9635848
[TBL] [Abstract][Full Text] [Related]
9. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
Arndt C; Morgenstern B; Hawkins D; Wilson D; Liedtke R; Miser J
Med Pediatr Oncol; 1999 Feb; 32(2):93-6. PubMed ID: 9950195
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
[TBL] [Abstract][Full Text] [Related]
11. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
Skinner R
Pediatr Nephrol; 2018 Feb; 33(2):215-225. PubMed ID: 28434047
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
13. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
14. Renal function in late survivors of Iranian children with cancer: single centre experience.
Arjmandi-Rafsanjani K; Hooman N; Vosoug P
Indian J Cancer; 2008; 45(4):154-7. PubMed ID: 19112203
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for ifosfamide nephrotoxicity in children.
Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
Lancet; 1996 Aug; 348(9027):578-80. PubMed ID: 8774570
[TBL] [Abstract][Full Text] [Related]
16. Renal toxicity and chemotherapy in children with cancer.
Ruggiero A; Ferrara P; Attinà G; Rizzo D; Riccardi R
Br J Clin Pharmacol; 2017 Dec; 83(12):2605-2614. PubMed ID: 28758697
[TBL] [Abstract][Full Text] [Related]
17. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
[TBL] [Abstract][Full Text] [Related]
18. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract][Full Text] [Related]
19. Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.
Rossi RM; Kist C; Wurster U; Külpmann WR; Ehrich JH
Pediatr Nephrol; 1994 Apr; 8(2):151-6. PubMed ID: 8018491
[TBL] [Abstract][Full Text] [Related]
20. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
Rossi R; Gödde A; Kleinebrand A; Riepenhausen M; Boos J; Ritter J; Jürgens H
J Clin Oncol; 1994 Jan; 12(1):159-65. PubMed ID: 8270973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
